FDA OKs a new triple hep C drug from Gilead -- plus the top 10 an­ti-vi­ral com­pa­nies in the world

Gilead’s world­wide hep C mar­ket may be shriv­el­ing at a fast pace, but the com­pa­ny con­tin­ues to field new com­bos that are wip­ing out re­main­ing pock­ets of dis­ease.

To­day came news that Gilead’s three-drug com­bi­na­tion of so­fos­bu­vir, vel­patasvir and a new drug called vox­i­lapre­vir has been ap­proved for the hep C phar­ma­copeia. It will now be sold as Vo­se­vi.

“Di­rect-act­ing an­tivi­ral drugs pre­vent the virus from mul­ti­ply­ing and of­ten cure HCV. Vo­se­vi pro­vides a treat­ment op­tion for some pa­tients who were not suc­cess­ful­ly treat­ed with oth­er HCV drugs in the past,” said Ed­ward Cox, di­rec­tor of the Of­fice of An­timi­cro­bial Prod­ucts in the FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER